SEC Filing Summary

Sean Maduck, President of Corcept Endocrinology, reported a series of transactions on August 3, 2026. Maduck acquired 20,305 shares of Common Stock at $8.27 per share and disposed of 20,305 shares of Common Stock at a weighted average price of $114.7045 per share. These transactions were executed under a 10b5-1 plan. Following these transactions, Maduck directly holds 9,755 shares of Common Stock. Additionally, Maduck has indirect holdings in various trusts and LLCs, including the Sean and Molly Maduck Living Trust, MMM 2025, LLC, SNM 2025 Grantor Retained Annuity Trust, SNM 2026 Grantor Retained Annuity Trust, and Duckhill Capital, LLC, totaling 119,755 shares. Maduck also holds a stock option to acquire 96,681 shares of Common Stock, exercisable at $8.27 per share, with an expiration date of February 10, 2027.